Why the study?
Oral PCSK9 inhibitors are an emerging class of lipid-lowering therapies that may improve adherence and accessibility compared with injectable agents, warranting an updated drug-specific synthesis including phase 3 enlicitide trials.
Population
4,065 adults with hypercholesterolaemia across five randomized controlled trials
Comparison
Oral PCSK9 inhibitors (enlicitide, NNC0385-0434, AZD0780) vs placebo
Design
GRADE-assessed systematic review and random-effects meta-analysis of randomized controlled trials
Answers are grounded in this paper and cite their sources.
Oral PCSK9 inhibitors substantially lower LDL-C with placebo-like safety; extends injectable evidence to convenient oral options for hypercholesterolemia.
Introduction Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging class of lipid-lowering therapies that may improve adherence and accessibility compared with injectable agents. Methods We systematically searched PubMed, Scopus, and Embase from inception to March 2026 for randomized controlled trials evaluating oral PCSK9 inhibitors (enlicitide, NNC0385-0434, AZD0780) in adults with hypercholesterolaemia. The primary outcome was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included any adverse events, serious adverse events, and discontinuation due to adverse events. Pooled estimates were calculated using random-effects models. Heterogeneity was assessed with I2 statistics. Certainty of evidence was evaluated using the GRADE framework. Results Five trials comprising 4,065 participants were included. Oral PCSK9 inhibitors significantly reduced LDL-C compared with placebo (mean difference −58.37%, 95% CI –59.99 to −56.75; I2 = 0%). In drug-specific subgroup analysis, enlicitide (phase 3) showed a reduction of −58.57% (95% CI –60.30 to −56.84; I2 = 0%), while other agents (phase 2) showed a reduction of −56.88% (95% CI –63.13 to −50.64; I2 = 39.7%). There were no significant differences between treatment and placebo for any adverse events (RR 0.99, 95% CI 0.97–1.02), serious adverse events (RR 0.94, 95% CI 0.63–1.40), or discontinuation due to adverse events (RR 1.05, 95% CI 0.88–1.25). Certainty of evidence was high for LDL-C reduction, any adverse events, and discontinuation due to adverse events, and moderate for serious adverse events. Discussion Oral PCSK9 inhibitors provide substantial LDL-C reductions with a safety profile comparable to placebo. These agents represent a promising oral alternative to injectable PCSK9-targeted therapies, though long-term cardiovascular outcome trials are still needed.
No takes yet. Share an insight, caveat, or question.
Chenchula et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: